Metabolic bone disease: romosozumab: practice question

A Orthopaedics question in the style of the NEET PG paper. Answer it first, then read why the right option is right and why each of the others is wrong.

Try it

Orthopaedics · Metabolic bone disease: romosozumab

Sample item

A monoclonal antibody that increases bone formation by neutralising an osteocyte-derived inhibitor of Wnt signalling is used for severe postmenopausal osteoporosis. Which drug is this?

Original practice item, not a recalled exam question. Nothing here is recorded.

The answer and the reasoning

D. Romosozumab

Romosozumab blocks sclerostin, which is produced by osteocytes, so Wnt signalling and bone formation rise while resorption falls. It is given for a limited period and is avoided in patients with recent myocardial infarction or stroke.

Option by option

  • A. Zoledronic acid

    Zoledronic acid is a bisphosphonate and not an antibody.

  • B. Denosumab

    Denosumab is an antibody against RANKL and acts by reducing osteoclasts.

  • C. Teriparatide

    Teriparatide is a peptide fragment of PTH and not a monoclonal antibody.

  • D. Romosozumab (correct)

    Correct. Sclerostin neutralisation by a monoclonal antibody is the action of romosozumab.

Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.

More Orthopaedics questions

Questions about this Orthopaedics question

What is the answer to this Orthopaedics question?

The best answer is D, Romosozumab. Romosozumab blocks sclerostin, which is produced by osteocytes, so Wnt signalling and bone formation rise while resorption falls.

Why is "Zoledronic acid" not the answer?

Zoledronic acid is a bisphosphonate and not an antibody.

Why is "Denosumab" not the answer?

Denosumab is an antibody against RANKL and acts by reducing osteoclasts.

Why is "Teriparatide" not the answer?

Teriparatide is a peptide fragment of PTH and not a monoclonal antibody.

What concept does this question test?

It tests Metabolic bone disease: romosozumab in Orthopaedics. It is given for a limited period and is avoided in patients with recent myocardial infarction or stroke.

How hard is this question?

We tag it as an application question: it asks you to use a fact on a patient or a finding. The tag is our own editorial judgement, not an official difficulty rating, so read the reason for every option, not only the answer.

How should I study Metabolic bone disease: romosozumab?

Pair each fracture with its classic complication and nerve injured. Then use the flashcards and the other Orthopaedics questions on this site to test what stuck.

Is this a real NEET PG question?

No. It is an original practice item (editorial status: sample, version 1). NextPrep does not publish recalled or leaked questions, and independent faculty review of this item has not been completed yet, so confirm important facts in a standard textbook.